‘Reduced malignancy as a mechanism for longevity in mice with adenylyl cyclase type 5 disruption’

Adenylyl cyclase type 5 in cardiac disease, metabolism, and aging

(2013) Stephen F. Vatner et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Src activation by β-adrenoreceptors is a key switch for tumour metastasis

(2013) Guillermo N. Armaiz-Pena et al.   Nature Communications

Common mechanisms for calorie restriction and adenylyl cyclase type 5 knockout models of longevity

(2012) Lin Yan et al.   AGING CELL

Prevention of heart failure in mice by an antiviral agent that inhibits type 5 cardiac adenylyl cyclase

(2012) Kosaku Iwatsubo et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Diabetes mellitus and cancer risk: Review of the epidemiological evidence

(2012) Kentaro Shikata et al.   CANCER SCIENCE

β-blockers: a novel class of antitumor agents

(2012) Yi Ji et al.   OncoTargets and Therapy

The induction of S100p expression by the Prostaglandin E2(PGE2)/EP4 receptor signaling pathway in colon cancer cells

(2011) Anupama Chandramouli et al.   CANCER BIOLOGY & THERAPY

Caloric restriction reduces growth of mammary tumors and metastases

(2011) M. S. De Lorenzo et al.   CARCINOGENESIS

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: Cross-talk with the androgen receptor

(2010) Dennis Merkle et al.   CELLULAR SIGNALLING

Adenylyl cyclase type 5 protein expression during cardiac development and stress

(2009) Che-Lin Hu et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

CREB in the Pathophysiology of Cancer: Implications for Targeting Transcription Factors for Cancer Therapy

(2009) K. M. Sakamoto et al.   CLINICAL CANCER RESEARCH